Abivax is approaching a pivotal inflection point as its lead asset obefazimod advances through late-stage clinical development for ulcerative colitis. The Phase 3 ABTECT induction trials delivered positive results in July 2025, demonstrating statistically significant clinical remission at the FDA primary endpoint for the 50 mg once-daily dose. The ongoing maintenance trial read-out, expected in late second quarter 2026, represents the important binary catalyst that determine whether the company can submit a New Drug Application in the second half of 2026 and transition toward commercial-stage operations. This quarter marked meaningful progress on the financial front as well, with the repurchase and cancellation of all outstanding royalty certificates in May 2026 for an aggregate $90 million, eliminating a persistent overhang and simplifying the capital structure.
The investment thesis rests on three variables. First, the Phase 3 maintenance data confirm the durability of remission observed in the induction trials and the prior Phase 2b open-label maintenance study, where 53 percent clinical remission was maintained at two years. The central metric is the 44-week maintenance remission rate, and the market signal be the top-line data release. Second, the company execute on its stated cash runway into the fourth quarter of 2027, which assumes positive maintenance data and an NDA submission in the second half of 2026. The central metric is quarterly cash burn relative to the €429.6 million balance as of March 31, 2026, and the market signal is each quarterly financial update. Third, the Crohn's disease program via the ENHANCE-CD Phase 2b trial provides optionality beyond ulcerative colitis, with 12-week induction data expected in the fourth quarter of 2026. The central metric is the induction remission and response rates, and the market signal is the data read-out.
If the maintenance trial succeeds, the equity re-rates toward a commercial-stage valuation framework with visibility to first revenue in 2027. If the maintenance trial fails, the obefazimod franchise value collapses and the company becomes a pure pipeline play with a follow-on candidate not yet selected, requiring significant dilution to fund continued operations. The binary outcome is unambiguous: the maintenance data read-out is the single most consequential event in the company's history.